This meeting aims to:
- Improve FDA and therapy developer understanding of the challenging aspects of living with sarcoidosis and the aspects of the disease that patients and caregivers would most like to see addressed by treatments, which, in turn, should be driven by patient preferences identified during clinical development and ultimately incorporated into product labeling.
- Provide a platform for individuals with a wide variety of experiences with sarcoidosis and to support improved representation of women and racially and ethnically diverse populations in clinical trials, both of whom are underserved and disproportionately impacted by sarcoidosis.
- Inform future FDA reviews of therapies for sarcoidosis by providing insight regarding the treatment outcomes of that matter most to people with sarcoidosis and their caregivers.
The externally-led Patient-Focused Drug Development (PFDD) meeting is a complement to FDA’s PFDD initiative. The patient input collected during this meeting and reported after this event will have a lasting impact on the lives of those with sarcoidosis as it will inform the development and regulatory review of new drugs for this rare disease.
If you are interested in learning more and/or would like to share your insights for potential inclusion in this meeting, please complete the form listed below.
Thank You to Our Sponsors
